Dendritic Cell and Tumor Cell Cancer Vaccines Market Opportunity Analysis-2027


Posted June 24, 2021 by SANJAYCMI

“Coherent Market Insights “DENDRITIC CELL AND TUMOR CELL CANCER VACCINES MARKET – GLOBAL TRENDS, ESTIMATES AND FORECASTS, 2020-2027″
 
Dendritic Cell and Tumor Cell Cancer Vaccines Market, by Antigen (CD8, CD4, HER2, T-Helper Cell, and Others), by Application (Glioblastoma Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Renal Cancer, Lung Cancer, and Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Cancer is an abnormal growth of cells in the body, also known as malignancy. It has the potential to replicate itself rapidly and invade into other body parts also. There are numerous types of cancer present. Dendritic cells (part of neuron) plays an important role in inducing anti-tumor activity. Hence, various strategies are being developed to treat cancer with the help of dendritic cell. For generation of dendritic vaccine, dendritic cells are cultured alongside the cancer cells. The vaccine, when induced into body stimulates the immune system to attack cancer cells.

Global Dendritic Cell and Tumor Cell Vaccines Market Drivers

Increase in research and development activities related to dendritic cell and tumor cell based vaccines are expected to accelerate the global dendritic cell and tumor cell vaccines market growth. For instance, in March 2015, Rockefeller University and Memorial Sloan Kettering Cancer Center conducted a phase II study of autologous dendritic cell vaccines (DC/PC3). It is being used as an immunotherapy in the prostate cancer. The vaccine was developed by patient’s own cells.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2753

Furthermore, in April 2016, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l., began its study on autologous dendritic cells loaded with autologous tumor homogenate in combination with the drug IL-2. It is being used for the treatment of patients with stage IV colorectal cancer. The purpose of study is to evaluate the consistency of the response of immune cells after completion of the treatment. Currently, the study is in its second phase of clinical trials. Hence, such research and development activities of dendritic cell and tumor cell vaccines are expected to impel the global dendritic cell and tumor cell vaccines market growth.

Approvals of vaccines by regulatory bodies are expected to drive the global dendritic cell and tumor cell vaccines market growth. For instance, in June 2018, Northwest BioTherapeutics received U.S. Food & Drug Administration (FDA) approval for its dendritic cell vaccine, DCVax – L. It is being used for the treatment of cancer type, glioblastoma. Its clinical study revealed that many patients survived for over one and half years after the vaccination. Hence, such approved vaccines based on dendritic cell are expected to drive the global dendritic cell and tumor cell vaccine market growth.

Global Dendritic Cell and Tumor Cell Vaccines Market Regional Analysis

North America is expected to be a dominant region in the global dendritic cell and tumor cell vaccines market, with increasing prevalence of cancer in the region. According to National Institutes of Health (NIH) data, in 2018, around 609,640 people died due to cancer and incidence rate was 439.2 per 100,000 men and women per year. The most occurring cancer type are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, and kidney and renal pelvis cancer. Hence, the higher prevalence of cancer may lead to higher demand for dendritic cell and tumor cell vaccines and thereby, expected to propel the global dendritic cell and tumor cell vaccine market growth.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/dendritic-cell-and-tumor-cell-cancer-vaccines-market-2753

Global Dendritic Cell and Tumor Cell Vaccines Market Restraints

Withdrawal of dendritic cell and tumor cell vaccines from its clinical trials are expected to hamper the global dendritic cell and tumor cell vaccines clinical progress. For instance, in March 2016, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, conducted its clinical trial for dendritic cell vaccine with radiotherapy. It was being studied for the treatment of renal cancer. However, it got withdrawn in its second phase of clinical trial (reason unspecified). Hence, this factor may have a negative impact on the global dendritic and tumor cell vaccine market growth.

Global Dendritic Cell and Tumor Cell Vaccines Market Key Players

Some of the major players operating in the global dendritic cell and tumor cell vaccines market include, JW CreaGene, Miltenyi Biotec, GlaxoSmithKline plc, NorthWest BioTherapeutics, ImmunoCellular Therapeutics, Ltd., EnoChian Biosciences, Medigene AG, DC Prime, Tella Incorporation, and CiMaas

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2753

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
-- END ---
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave
# 3200 Seattle, WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags Dendritic Cell and Tumor Cell Cancer Vaccines Market Share , Dendritic Cell and Tumor Cell Cancer Vaccines Market Research , Dendritic Cell and Tumor Cell Cancer Vaccines Market Analysis
Last Updated June 24, 2021